Advertisements

Climene (Estradiol)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Climene (Estradiol)

Quick Facts

Property Description
Active Ingredients Estradiol valerate, Cyproterone acetate
Form Coated oral tablets
Pharmacological Class Estrogen and Progestogen (Sequential Combined HRT)
General Purpose Hormone substitution to relieve symptoms of estrogen deficiency
Origin Estradiol valerate is a synthetic ester of natural 17beta-Estradiol

What Type of Medicine is Climene (Estradiol)?

Climene is a prescription-only medicine globally recognized as a Hormone Replacement Therapy (HRT) product. It is classified as a sequential combined HRT, a type of systemic therapy belonging to the Steroid hormone class. This formulation is delivered as coated oral tablets that contain two distinct active compounds administered in a specific, cyclic pattern. The sequential design is a distinctive feature, used to provide hormone substitution while managing the effects of estrogen on the uterine lining.


What is the Composition and General Purpose of Climene?

The medication contains the active ingredients Estradiol valerate and Cyproterone acetate. Estradiol valerate is the estrogen component, which is a synthetic ester of the natural human hormone, 17beta-Estradiol, chosen for its effective absorption when taken orally. The Cyproterone acetate component serves as the necessary progestogen, combined with the estrogen during a portion of the cycle to establish a hormonal balance. The general purpose of this therapy is hormone substitution to counteract the physiological changes resulting from estrogen deficiency. This approach restores hormonal stability, offering relief from pervasive discomfort in the patient population targeted.

Advertisements

What side effects are possible with Climene (Estradiol)?

Possible Side Effects and Safety Information

The safety profile of Climene, as documented in official regulatory sources, outlines adverse reactions categorized by frequency and the organ systems affected.

Adverse Reaction Scope

Category Description
Frequency Classification Very Common (ge 10%): Headache, tiredness. Common (ge 1% to < 10%): Depressed mood, weight change, gastric complaints, nausea, breast pain/tension, irregular uterine bleeding/spotting, and fatigue. Rare (ge 0.01% to < 0.1%): Venous thromboembolism (VTE), benign and malignant liver tumours, and hypersensitivity reactions.
System-Organ Classes Adverse reactions are officially reported across classes including Vascular Disorders, Hepatobiliary Disorders, Reproductive System and Breast Disorders, and Neoplasms (Benign, Malignant).

Serious Safety Considerations

The regulatory label highlights rare but serious risks associated with combined Hormone Replacement Therapy (HRT). These include an increased risk of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, as well as Arterial Thromboembolism (Stroke, Myocardial Infarction). There is also an increased risk of certain Malignancies, including Breast Cancer, Endometrial Cancer, and Ovarian Cancer. The development of Benign or Malignant Liver Tumours is also a documented serious adverse reaction.

Time-Related and Population Safety Notes

Time-Related Patterns specify that the risk of VTE is highest during the first year of use, and breakthrough bleeding is more likely during the first few months of therapy. Population-specific safety notes indicate that use in women aged 65 years and older may be associated with an increased risk of probable dementia. The medicine is contraindicated in severe hepatic disease.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Climene (Estradiol valerate and Cyproterone acetate) overdose describes the expected clinical manifestations resulting from acute, excessive exposure to the hormonal components. Documented acute presentations typically include nausea and vomiting, breast tenderness or tension, and may be followed days later by vaginal withdrawal bleeding or spotting. The effects documented in regulatory sources are generally classified as non-life-threatening consequences of overexposure.

For any suspected ingestion of a dose above that prescribed, the official labeling mandates an immediate emergency response. Urgent medical help is required; individuals must seek immediate medical attention and contact a poison control center for professional guidance. The official prescribing information states explicitly that no specific antidote is known to exist for Climene overdose.

Management procedures are defined as symptomatic and supportive treatment. This may involve medical interventions such as the administration of activated charcoal and the provision of intravenous fluids in certain cases. Continuous monitoring is required, including the assessment of vital signs and necessary follow-up blood and urine tests, as stipulated in regulatory guidance for managing acute hormonal overdose.

Advertisements

Therapeutic Uses of Climene (Estradiol)

What Climene (Estradiol) treats: Main Uses and Benefits

Climene is commonly used for managing conditions stemming from estrogen deficiency, a therapeutic approach known as Hormone Replacement Therapy (HRT). This therapy is relevant for substituting hormones that are no longer produced in sufficient amounts due to menopause. The sequential combined formulation is applied across domains where additional symptomatic support is needed, assisting with relief in situations involving certain distressing symptoms.

Climene is commonly used to help manage symptoms related to systemic imbalance and localized tissue changes. This includes symptoms that interfere with daily functioning, such as hot flashes, night sweats, and complaints arising from vaginal dryness or irritation. It also may assist with managing accompanying neurovegetative issues, including mood changes and sleep disturbances. This supportive relief contributes to easing the overall symptom load and helps patients cope more steadily with these disruptive manifestations.


Quick Fact: Relief for Key Symptom Domains
Vasomotor Symptoms (hot flashes, night sweats)
Symptoms related to Irritative States (dryness, irritation)
Neurovegetative Complaints (mood, sleep)
Skeletal Health (support related to maintaining functional stability)

Regulatory References

  1. NIH MedlinePlus overview on HRT
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Climene (Estradiol)?

Climene (Estradiol valerate and Cyproterone acetate) is an HRT product intended for postmenopausal women with an intact uterus.

Contraindicated Populations (Must Not Use)

Official regulatory documents state that Climene is contraindicated (must not be used) in women with a history or current diagnosis of specific severe conditions. These include breast cancer or suspicion thereof, oestrogen-dependent malignant tumours, previous or current venous or arterial thromboembolic disease (such as Deep Vein Thrombosis or Stroke), and known thrombophilic disorders. The medicine is also strictly prohibited in the presence of severe hepatic disease, liver tumours, undiagnosed genital bleeding, untreated endometrial hyperplasia, or a history of Meningioma (a restriction tied to the Cyproterone acetate component).


Population and Age Restrictions

Category Regulatory Status
Pregnancy/Lactation Contraindicated (Must not be used)
Children and Adolescents Not indicated for use
Women over 65 Limited experience is available

Use of Climene requires strict medical supervision in patients with conditions like Diabetes Mellitus, Hypertension, Leiomyoma (uterine fibroids), or Endometriosis.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Climene (Estradiol valerate and Cyproterone acetate) has formally documented interaction patterns primarily involving the hepatic enzyme system responsible for drug metabolism. Both active components are subject to metabolism, notably by the Cytochrome P450 3A4 (CYP3A4) enzymes.

Pharmacokinetic Interactions

Co-administration with CYP3A4 inducers—such as certain anticonvulsants (e.g., phenytoin, carbamazepine, topiramate) and antituberculosis agents (e.g., rifampicin)—is documented to significantly reduce the plasma concentrations of both hormones. This reduction in exposure may compromise the therapeutic effect and alter the uterine bleeding profile. Conversely, potent CYP3A4 inhibitors may lead to increased plasma concentrations of the active components. The herbal product St. John’s Wort (Hypericum perforatum) is also specifically documented as a CYP3A4 inducer that reduces hormone exposure.

Contraindicated Combinations and Restrictions

Climene is contraindicated for co-administration with specific combination therapies for Hepatitis C, including regimens containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), due to the mandated risk of severe Alanine Transaminase (ALT) elevations. Furthermore, the presence or history of severe hepatic disease is classified as a metabolic contraindication, requiring close supervision for patients with non-severe impaired hepatic function.

Advertisements

Mechanism of Action

Estradiol acts as an agonist by binding to and activating the intracellular Estrogen Receptors (ERs), specifically ERalpha and ERbeta. Being a lipophilic molecule, it readily diffuses across the cell membrane to reach the cytoplasmic and nuclear receptors in target tissues, including the reproductive tract, bone, and central nervous system.

Upon ligand binding, the receptor undergoes a conformational change, leading to its dissociation from heat shock proteins, subsequent dimerization, and translocation to the nucleus. This dimerized complex functions as a ligand-activated transcription factor. In the nucleus, it binds directly to specific DNA sequences known as Estrogen Response Elements (EREs) in the promoter regions of target genes (the genomic pathway). This interaction recruits co-activators and basal transcription machinery, resulting in the modulation of target gene transcription and subsequent protein synthesis.

Additionally, estradiol also initiates rapid, non-genomic signaling pathways by interacting with a sub-population of ERs localized at the plasma membrane or with the G-protein coupled estrogen receptor GPER1. These interactions quickly activate intracellular signaling cascades, such as the MAPK and PI3K/Akt pathways, which can lead to rapid cellular responses like ion channel modulation and the phosphorylation of other transcription factors, further contributing to the system-level physiological modulation of reproductive, skeletal, and cardiovascular function.

Advertisements

Dosage and Administration Information

Climene is a sequential combined Hormone Replacement Therapy (HRT) administered strictly via the oral route as part of a fixed, continuous, 28-day cycle. The treatment is designed as a daily sequential regimen, ensuring that a progestogen component is added during a portion of the cycle.

Official Dosing and Administration

The standard adult dosing regimen requires the daily intake of one coated tablet at approximately the same time each day. The cycle pack contains 21 active tablets taken in a specific order, followed by a 7-day tablet-free interval.

Cycle Phase (Days) Tablet Color & Composition Regimen Strength
Days 1–11 White (Estradiol Valerate) 2 mg EV
Days 12–21 Pink (Estradiol Valerate + Cyproterone Acetate) 2 mg EV + 1 mg CPA
Days 22–28 None (Tablet-free interval) 0 mg

Tablets must be swallowed whole with sufficient liquid. Upon completion of the 28-day cycle, a new pack is started immediately, without a further break, to maintain continuous therapy.

Administration Rules for Specific Scenarios

Starting the treatment is determined by the patient’s status. For women who are still menstruating, therapy is typically initiated on Day 5 of the menstrual cycle (Day 1 being the first day of bleeding). For postmenopausal women or those with amenorrhoea (absence of periods), treatment can be started on any day.

If a dose is missed, the tablet should be taken as soon as possible, but only if it is within 12 hours of the usual time. If more than 12 hours have passed, the missed dose must be skipped to avoid disrupting the hormone schedule. The daily intake of one tablet without interruption of the cycle is the core procedural requirement for this therapy.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Climene (Estradiol)

The research available for Climene (estradiol valerate and cyproterone acetate) is part of the broader scientific literature on Hormone Replacement Therapy (HRT). This section describes the types of studies that have been conducted, the areas of health that have been examined, and what remains uncertain according to the evidence record.


Evidence for use in Managing Symptoms of Estrogen Deficiency

This section will summarize the available research, including short-term randomized controlled trials (RCTs) and systematic reviews, that have evaluated research into moderate to severe vasomotor symptoms and other neurovegetative complaints in postmenopausal women with an intact uterus.

The research for this category involves controlled studies, often comparing the therapy to an inactive substance (placebo) to evaluate symptom changes. These RCTs were used in research exploring how symptoms change over time in postmenopausal women with an intact uterus with symptoms like hot flashes and night sweats. Studies also monitored patient-reported outcomes describing perceived discomfort related to sleep quality, mood, and daily functioning.

The findings describe patterns observed in the studies over the short- to medium-term periods, typically ranging from a few weeks up to one year. Research highlights changes measured during the study period in the frequency and intensity of episodic symptom patterns such as vasomotor episodes. Additionally, studies report how symptoms evolved in the observed populations, providing insight into how patient-reported experiences were recorded while on the sequential combined regimen.

However, the evidence is limited for specific aspects of this formulation. Long-term outcomes are not well characterized regarding sustained symptomatic stability beyond the one-year follow-up of many trials. Furthermore, the core evidence for efficacy relies on extrapolation from studies of various HRT combinations, meaning comparative evidence is lacking for how this specific regimen performs against every other available combined HRT product.


Evidence on Research into Postmenopausal Osteoporosis

This part outlines the structural evidence regarding research into systemic estrogen replacement and bone mineral density (BMD) and fracture incidence.

Research has was studied for the long-term effects of systemic estrogen therapy on skeletal health outcomes related to systemic or functional imbalance. This research primarily involves long-term observational studies and controlled trials that monitored changes in bone mineral density (BMD), usually measured in the hip and spine, over periods often lasting five years or more. These studies explored whether the therapy was associated with patterns in the rates of fractures (e.g., hip or spine) compared to control groups.

The findings from these long-term trials indicate that the therapy appears to be associated with patterns of BMD stabilization compared to a lack of treatment in the populations studied. Studies report that BMD levels evolved in the observed groups over the course of the research period. This evidence contributes to the broader evidence landscape regarding how hormone substitution is recorded to affect bone structure, particularly in women with conditions marked by functional limitations related to bone fragility.

Long-term data remain insufficient beyond the observation windows of the key multi-year studies. Importantly, results apply only to the populations studied, which were generally restricted to high-risk women. Therefore, data for certain groups remain insufficient, and the findings describe group patterns, not personal outcomes for all postmenopausal women.


Long-term Follow-up and Study Durability

This section synthesizes the available data regarding long-term observation periods for this type of combined Hormone Replacement Therapy (HRT). It will describe the duration of follow-up typical in key studies, addressing the evidence base for effects maintained beyond the initial treatment phase.

Research often examined temporary physiological imbalance in trials lasting six months to one year for symptom management. However, for outcomes like BMD maintenance, studies were conducted over defined time intervals of up to five or more years of follow-up.

Overall, the follow-up durations were limited in many studies focusing on the acute relief of symptoms. Evidence derived from settings with varying symptom burdens helps contextualize how patients reported their experience over the short term, but there is limited information for long-term outcomes regarding the durability of these effects once treatment is sustained for decades.


Evidence in Specific Patient Populations

This segment will identify and outline research findings, where they exist, concerning the use of this therapy in specific patient groups, such as studies focusing on women in early postmenopause or those defined by the severity of their symptoms.

The populations most extensively examined in the key studies were women who were either in early postmenopause or under age 60 who were experiencing moderate to severe vasomotor symptoms. The research explored these groups as they represent the population for whom the therapy was evaluated in.

Subgroup findings are uncertain for women who are substantially older or those with specific pre-existing comorbidities, as these were often excluded from the core controlled trials. Therefore, data for certain groups remain insufficient, meaning the research does not determine whether an individual in these less-studied groups will respond similarly.


Research Gaps and Areas of Uncertainty

This concluding section clarifies the known limitation in the research base, including any heterogeneity across findings, the generalizability of results from studies using different combinations, and areas where more targeted or longer-duration research may be needed to complete the scientific record.

While a large volume of research contributes to the broader evidence landscape of HRT, evidence quality varies across studies when looking specifically at the Estradiol valerate/Cyproterone acetate combination. Data for this precise formulation often was observed in some studies that were smaller than the large multi-center trials used for other HRT types.

Research describes the need for more targeted investigation into long-term outcomes for bone health and sustained symptom relief beyond the typical observation periods. Furthermore, comparative evidence is lacking for how this combined regimen performs against all other progestogen components when used in sequential HRT. These factors mean that some results remain uncertain in specific comparisons and long-term scenarios.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Climene (Estradiol) (FAQ)

Q: Can Climene be used for symptoms other than menopause, such as for transgender hormone therapy?

A: Climene is officially indicated for Hormone Replacement Therapy (HRT) specifically to relieve symptoms of estrogen deficiency in postmenopausal women who have an intact uterus. Regulatory documentation does not specify its use for other conditions or patient populations.


Q: How quickly should I expect to see relief from hot flashes after starting Climene?

A: Official studies examining this medication and similar combined HRTs generally report that changes in vasomotor symptoms (like hot flashes) are observed within the first few weeks of starting treatment. However, the exact time it takes to experience relief can vary for each individual.


Q: How long can a person safely stay on Climene for Hormone Replacement Therapy?

A: Regulatory documents state that Hormone Replacement Therapy is officially described as being used for the shortest duration possible at the lowest effective dose. Official guidance requires a medical re-evaluation by a healthcare professional at least annually to determine if treatment should continue.


Q: Are there any dietary restrictions or foods/drinks that should be avoided while on Climene?

-A: Official regulatory texts primarily focus on interactions with certain medications and herbal products like St. John's Wort. There are no specific dietary restrictions or common food or drink warnings (such as grapefruit juice) that are explicitly listed in the key drug interactions sections of the official product information.


Q: Is Climene safe to use if I have a history of migraines?

A: Official warnings note that treatment is typically discontinued immediately if a patient experiences a first-ever migraine headache or if headaches become frequent or unusually severe. A history of migraine is a condition officially listed as requiring close medical supervision.


Q: Does Climene affect libido (sex drive)?

A: Official labeling for the components in Climene typically reports changes in libido as an uncommon side effect. This change is often noted as a decreased libido (sex drive).


Q: Will I still get a monthly withdrawal bleed while taking Climene?

A: Yes. Climene is a sequential combined HRT which includes a progestogen component for part of the cycle. The treatment schedule, which involves a tablet-free interval, is specifically designed to result in a predictable withdrawal bleed (bleeding similar to a menstrual period).


Q: Is it true that taking Climene can affect my liver function or require blood tests?

A: Climene is contraindicated (must not be used) in cases of severe liver disease. For patients with certain liver issues, official warnings state that liver function is monitored by a healthcare professional, which may include periodic blood tests to check enzyme levels.


Q: Can Climene be used to prevent osteoporosis after menopause?

A: Yes. According to official therapeutic indications, Climene is indicated for the prevention of osteoporosis (bone thinning) in postmenopausal women. This is reserved for women who are at a high risk of fractures and cannot take other treatments for osteoporosis.


Q: Does Climene interact with common supplements like St. John's Wort or evening primrose oil?

A: The product is known to interact with the herbal supplement St. John’s Wort, which can reduce the effectiveness of the hormone components. Official guidance warns against using any herbal product known to affect liver enzymes, which are key for processing this medication.


Q: Does Climene cause fluid retention or swelling (edema)?

A: Official side effect documentation lists weight change which can be associated with fluid retention (also known as edema). General estrogen therapy is noted as requiring caution in patients who are prone to retaining fluid.


Q: If I stop taking Climene, will my menopausal symptoms return?

A: Hormone Replacement Therapy works by providing hormones to counteract a functional deficiency. It is generally understood that most patients experience a return of menopausal symptoms upon discontinuation, as the underlying estrogen deficiency persists.


Q: How does the estrogen in Climene differ from the estrogen in birth control pills?

A: Climene contains Estradiol Valerate, which is a substance that is converted in the body into the natural human hormone, 17beta-Estradiol. In contrast, most oral birth control pills contain a synthetic estrogen called Ethinyl Estradiol, which is chemically modified to be significantly more potent and metabolically stable.


Q: What does the official labeling say about Climene and its effect on anxiety or depression?

A: The official labeling lists depressed mood as a common side effect of the medication. Additionally, patients with a known history of clinical depression require strict medical supervision when undergoing this therapy.


Q: Is there any information about Climene and changes in vision or contact lens tolerance?

A: The official side effect listing includes changes in vision and contact lens intolerance (meaning the lenses may cause discomfort) as reported uncommon side effects associated with HRT.


Q: What should I do if I notice signs of a blood clot while taking this medicine?

A: Regulatory information explicitly lists the symptoms of serious clotting events, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as conditions that require immediate medical attention. The occurrence of these symptoms is a documented reason for treatment to be stopped.


Q: Is Climene considered effective for treating atrophy of the skin and urogenital tract?

A: Yes. According to official therapeutic indications, Climene is used for treating symptoms of estrogen deficiency. This specifically includes the treatment of urogenital atrophy, which refers to changes like dryness and irritation of the vaginal and vulval tissues.


Q: Does Climene affect the need for diabetes medications?

A: Official warnings classify Diabetes Mellitus as a condition that requires strict medical supervision during therapy. This is because estrogen/progestogen treatment may affect glucose tolerance and potentially require an adjustment in the dosage of antidiabetic medication by a healthcare professional.


Q: Are the reported side effects of Climene generally temporary?

A: Regulatory documents indicate that certain common side effects may lessen over time. For example, breakthrough bleeding and spotting are specifically noted as being more common during the first few months of therapy, suggesting a potential reduction in frequency thereafter.


Q: Is Climene intended to act as a contraceptive (birth control)?

A: No. Climene is classified as a Hormone Replacement Therapy (HRT) intended for postmenopausal women. It is not designed for and is not considered effective as a contraceptive (birth control method).


Q: Does Climene affect the health of the gallbladder?

A: The development of gallbladder disease is an adverse event that has been associated with general estrogen use. Patients with a history of gallbladder problems are listed as potentially requiring medical supervision during therapy.


Q: What should be checked by a doctor before starting Climene therapy?

A: Official guidance states that a full medical history (personal and family) must be taken before starting treatment. This is followed by a complete physical and gynecological examination, which typically includes checks for blood pressure, breasts, and the pelvic region, with follow-up checks performed periodically.


Q: Is there an increased risk of migraine-like headaches when using Climene?

A: Official documentation lists Headache as a very common side effect. Furthermore, the development of a migraine-like headache or an unusually severe headache is specifically listed as a warning sign that requires immediate review and possible discontinuation of the medication.


Q: Can Climene be used in women with primary ovarian failure?

A: While the official label is for postmenopausal women, the use of Hormone Replacement Therapy is widely supported by clinical research for women with Primary Ovarian Insufficiency (POI) (also known as Primary Ovarian Failure). POI is a condition that results in estrogen deficiency and menopausal symptoms at a young age.


Q: Can the medication interfere with mammography screening results?

A: Combined Hormone Replacement Therapy is known to increase mammographic density in breast tissue in some women. This change in density may potentially make the radiological detection of breast cancer more difficult during screening.


Q: Does Climene contain lactose or sucrose that I should be aware of?

A: Yes. The tablets typically contain the excipients lactose and sucrose. Official warnings note that patients who have rare hereditary problems related to intolerance of galactose or fructose should be aware of these components.


Q: If I have a history of epilepsy or seizures, can I use Climene?

A: A history of epilepsy is officially listed as a condition that requires strict medical supervision and close monitoring throughout the course of therapy.


Q: Is there information on how Climene affects heart palpitations?

A: Official side effect listings report that Tachycardia (rapid heartbeat) and palpitations (a rapid or irregular heartbeat sensation) are rare cardiovascular side effects associated with the use of estrogen/progestogen combinations.


Q: Why might a doctor need to supervise patients with varicose veins while on Climene?

A: Regulatory information notes that severe varicose veins are associated with an increased risk of Venous Thromboembolism (VTE), which is a rare but serious risk of HRT. Patients with this condition therefore require strict medical supervision to monitor for potential clotting issues.


Q: Do other medicines, like certain antibiotics, reduce the effectiveness of Climene?

A: Yes. Rifampicin (an antibiotic) and Griseofulvin (an antifungal) are specifically listed in the interactions section as medications that can reduce hormone plasma concentrations and the effectiveness of HRT.


Q: What kind of skin changes (e.g., rash, itching) are sometimes associated with Climene?

A: Official side effect listings report that Rash, itching (pruritus), and hypersensitivity reactions are generally listed as rare side effects associated with the active components of the medication.


Q: Does Climene provide a treatment for mood disorders related to the climacteric (menopause transition)?

A: Climene is indicated to relieve a range of estrogen deficiency symptoms, which includes neurovegetative complaints and discomfort related to mood and sleep quality. However, its primary purpose is hormone substitution, not the specific treatment of clinical mood disorders.

Advertisements

How should Climene (Estradiol) be stored and disposed of?

Official Storage and Disposal Requirements

Climene (Estradiol valerate/Cyproterone acetate) tablets must be stored according to regulatory guidelines to ensure stability and safety. The official labeled storage condition requires the product to be kept at room temperature, specifically below 30 C. The medicine must be stored in its original pack and maintained out of the sight and reach of children.

Requirement Official Instruction
Temperature Below 30 C
Protection Store in original pack; Keep out of sight and reach of children
Disposal Do not dispose of via wastewater or household waste; Follow local regulations for pharmaceutical returns.

Unused or expired product must not be discarded in general trash or flushed, but should be handled according to local waste regulations or returned via official drug take-back schemes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Climene (Estradiol) found in:

A-Z Index: